Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Total revenues		$ 100,229	$ 54,440	$ 321,545	$ 173,405
Collaboration expense to Pfizer		26,808	12,086	67,242	25,912
Selling, general and administrative	[1]	86,380	72,125	249,671	192,118
Research and development		31,518	25,726	82,324	82,886
Total operating costs and expenses		152,124	114,180	416,512	308,813
Loss from operations		(51,895)	(59,740)	(94,967)	(135,408)
Interest expense	[2]	6,118	3,479	15,131	10,478
Interest income		(1,591)	(70)	(3,095)	(248)
Loss before income taxes		(56,422)	(63,149)	(107,003)	(145,638)
Income tax expense		1,205	296	17,482	1,058
Net loss and comprehensive loss		(57,627)	(63,445)	(124,485)	(146,696)
Net loss and comprehensive loss		$ (57,627)	$ (63,445)	$ (124,485)	$ (146,696)
Net loss per common share - basic (in USD per share)		$ (0.59)	$ (0.68)	$ (1.29)	$ (1.59)
Net loss per common share - diluted (in USD per share)		$ (0.59)	$ (0.68)	$ (1.29)	$ (1.59)
Weighted average common shares outstanding - basic (in shares)		96,859,108	93,474,985	96,155,644	92,514,657
Weighted average common shares outstanding - diluted (in shares)		96,859,108	93,474,985	96,155,644	92,514,657
Product revenue, net
Total revenues		$ 61,422	$ 29,268	$ 152,720	$ 61,885
Cost of product revenue		7,418	4,243	17,275	7,897
Pfizer collaboration revenue
Total revenues		29,307	25,172	109,025	79,853
Accord license and milestone revenue
Total revenues		5,000	0	55,000	0
Richter license and milestone revenue
Total revenues		4,000	0	4,300	31,667
Other revenue
Total revenues		$ 500	$ 0	$ 500	$ 0

[1] Includes $1,362 and $3,766 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2022, respectively. Includes $1,337 and $3,784 of related party expense (inclusive of third-party pass-through costs) for the three and nine months ended December 31, 2021, respectively. See Note 5.

[2] Includes $6,118 and $14,563 of interest expense under the Sumitomo Pharma Loan Agreement for the three and nine months ended December 31, 2022, respectively. Includes $2,871 and $8,660 of interest expense under the Sumitomo Pharma Loan Agreement for the three and nine months ended December 31, 2021, respectively. See Note (5C).